Rocket Pharma secures credit facility for up to $150 million from Hercules Capital
RCKT•Rocket Pharmaceuticals entered a credit facility with Hercules Capital for up to $150 million to support its Danon disease program. Rocket expects its cash resources, including the initial $35 million draw, to fund operations into Q3 2028; further draws could extend its runway into 2029.
1. Facility terms
The facility funded $35 million at closing, with another $35 million available at Rocket’s option during specified periods. An additional $30 million is tied to a Danon clinical milestone, while a further $50 million is subject to Hercules investment committee approval. The agreement includes a 30-month interest-only period and a 48-month maturity, with milestone-based extension options.
